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INTRODUCTION 
Leptaden is a herbal drug which was recently introduced to the 
ma_rket by Alarsin Phannaceuticals', Bombay, India. It consists of the 
extracts of two indigenous medical plants, namely Leotadenia !"et iculatc. 
{Jeevanti) and Breynia patens (Kamboji) in equal proportions. 
In 194 7 ,· ·Patel first drew the attention of gynaecologists to the 
usefulness of Leptaden in habitual abortions and allied conditi:ms in 
women and later on pointed out its lactogenic and galactagog-1..: e 
properties. His original observations are supported by growinq cl inicc l 
experience over a twenty year period of medical practice. Publi s hed 
clinical experience shows that in most cases Leptaden stimula tes ., 
lactation within twelve hours; flow is easy and lactation is ma i ntained 
after the Lepta den treatment is discontinued. The drug has prcduced 
no observable hannful effects on the health of women or cows. 
On the basis of the lactogenic and galactagogue properties of 
the Leptaden, the research reported in this thesis was underta ken with 
the following objectives: 
1. To determine the effects of feeding Leptaden to dafry cows 
on milk production and composition. 
2. To determine the apparent effects of Leptaden on thyroid 
activity. 
3. To determine the effects of Leptaden on some other physio-
logical acµvities of dairy cows. 
2 
L1TERl\TURE REVIEW 
Various kinds of drugs have been tried with dairy cows in an 
attempt to increase milk yield or to increase the percentage of fat in 
the milk. 
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The mechanism by which drugs influence milk yield is not well 
known. Some workers (18, 28, 29) have taken advantage of the known 
physiological properties of various drugs. Under certain circumstances, 
some d rugs may act as galactagogues; however, work with laboratory 
and farm animals has demonstrated the galactopoietic powers of few 
drugs (28). Much o.f the research in this area has been done with 
mammals other than dairy cows. Thus, the results may not be direqtly 
applicable to the dairy cow because of certain generic qifferences in 
physiological activity. 
The possible ways by which drugs may influence the mammary 
gland include the following _(2 9): 
(1) Direct action of the drug on the protoplasm of the cells, 
either stimulating or inhibiting the action of the cells. 
(2) Neural stimuli from the reproductive tract probably increasing 
the release, via the hypothalamus of prolactin and ACTH 
which in turn cause milk secretion. 
(3) The action of the heart may be_ influenced and produce an 
increase or decrease in the .rate of blood circulation, thus 
altering the volume of }?lood and the amount of nutrients 
which would pass through the udder. 
(4) The general vasomotor influence of drugs, increasing or 
decr:easing the amount of blood passing through the udder 
by vaso-constriction of arterioles in the mammary gland. 
(5) The effects of drugs on metabolism, through their influence 
on digestion apd absorption, and ultimately on the amount 
of nutrients available for milk and fat production. 
(6) The action of the drugs on organs i.ndirectly associated 
with the mammary gland might influence milk and fat 
production. 
(7) Some drugs may initiate lactation, probably by suppressing 
the prolaqtin-inhibiting factor in the hypothalamus. 
(8) Some drugs like thyroactive substances may stimulate milk 
production by increasing the general metabolic rate of the 
alveolar cells of the mammary gland with the increased 
yield being regarded as part of the generalized effect. The 
concomitant increase in heart rate usually noted during the 
administration of these types of drugs would also increase 
the supply of milk precursors reaching the gland. Further, 
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these drugs may increase the sec;;retion of galactopoietic 
factors by the anterior pituitary. 
(9) The increased milk produc.tion associated with exogenous 
administration of a hormone(s) indicates a sub-optimal 
secretion of that hormone(s). On the other hand, such 
responses to hormones may represent pharmacological 
responses and be unrelated to the normal secretion rate 
of hormone(s) . 
As these actions may be brqught about separately or in almost any 
· combination as well as in varying degrees of intensity, the problem 
of the influence of drugs on milk production is a complicated one. 
The observations that the individual cows vary in degree of suscepti-
bility to drug action increase the complexity of the problem. 
Effects of Leptaden 
Patel (33) first drew the attention of gynaecologists to the 
usefulness of Leptaden in habitual abortions and allied conditions in 
women, then later on pointed out its lactogenic and galactagogue 
properties. His original observations were subsequently supported 
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by Mangeshikar (2 7), Naik (31) and others (1, 34). Trivedi (42) 
observed that in women lactation started in 8 to 12 hours after Leptaden 
treatment and it was maintained after the treatment was discontinued. 
He did not find any detrimental effects of the drug on the health of 
child or mother. 
The need for a satisfactory lac~ogen and galactagogue for women 
prompted Malati Deshpande and Asher (9) to conduct some studies on 
Lepta den. They observed that the drug stimulated lactation in 6 to 10 
hours after administration. The propulsion of milk seemed to be 
facilitated in those cases where there was secretion but no easy flow. 
Lactation was maintained when the treatment with proper dosage was 
continued. 
Malati Gokhale (14) concentrated her studies on human patients 
with problems of lactation failure due to scanty secretion or no 
secretion. Her observations suggested that Leptaden stimulated 
lactation in most of the cases if given in proper dosage and started 
at the proper time. In some cases the stimulation was rather dramatic 
in onset and quantity_ of lactation. In her opinion the drug has both 
· galactokinetic and galactopoietic actions. Milk flow was good in 
almost all cases. Lactation was maintained from 2 to 6 months after 
cessation of Leptaden administration. She suggested that Leptaden 
should be started on the first day of delivery and in multipara· with 
history of lactation failures, during the last one or two months of 
pregnancy. 
Leptaden seems to have some definite efficacy from conception 
to lactation. Initially this drug was tried as a prophylaxis in a few 
6 
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selected cases of primigravidae during the first three months of 
pregnancy. This was intended t_o reduce common ptimigravida hazards 
Uke severe morning sickness, possible pregnancy toxaemia or delivery 
hazards. It gave satisfactory results as prophylaxis. Prolonged and 
continuous use of Leptaden for about 6-7 months had no observable 
adverse effects (34). Achari (1) reported that Leptaden, by acting 
as a uterine sedative either by direct action or through hormone 
mechanism, reduced the incidence of recurrent abortions. 
Using Leptaden at the rate of one tablet (0. Sg/tablet) tl].rice 
daily, Gupta and Kishore (17) treated 150 patients; 125 postnatal and 
2 6 prena tal. Sixty percent of theru responded well, 12% partially and 
28% gave no response. In patients with a deficiency after initiation, 
83. 3% showed good res pons~. This drug may be recommended in 
routine treatment in nonnal failure of lactatio!}. 
Moulvi (30) first drew the attention of the veterinary profession 
to the lactogenic properties of Leptaden in buffaloes. He administered 
five tablets of Leptaden to · low milk producing buffaloes twice daily 
after calving and obtained increased milk yields. 
Vaishnav and Buch (43) fed Leptaden at the rate of five tablets 
twice daily to six Gir cows which calved in the same month and whose 
milk yield was poor. Of the six experimental cows, two showed an 
8 
increase in milk yield and one maintained its lactation after losing 
' 
the calf. Although the drug had some favorable effects in individual 
cases, sta tistical analysis of the data did not indicate any significant 
increas f ·' per da,y. 
Anjaria and Gupta (2) studied the comparative lactogenic 
properties of Lt:;ptadenia reticulata plant and Leptaden tablets in goats, 
sheep, buffaloes and cows. The goats and sheep were in declining 
phases of lactation, the cows were in stable phase and the buffaloes 
were in_ ascending phase of lactation. Both drugs produced significant 
galactopoietic response in most of the experiments. 
Sharma (3 7) reported that the drug has some other beneficial 
effects in cases of retained placenta in buffaloes besides its 
galactopoietic action. Retained placenta came out in most of the 
cases, and milk yield was not impaired. 
Kaikini et! al~ (23) reported that Leptaden was useful in milk 
irregularities in buffaloes. Clinical response was good in 54. 7%, 
partial in 28. 7% and nil in 14. 2% of the 16 cases treated. 
Kulkarni (2 5) studied the efficacy of Leptaden in conditioned 
hypogalactia in buffaloes. Animals which recovered from an attack 
of mucosa! disease had suffered tissue dehydration as a consequence 
of diarrhea. Such animals rarely return to lactation. Leptaden was 
fed at the rate of 10 to 20 -tablets per day for 8 to 12 days to 10 
buffaloes when they showed desire to eat concentrate. Six animals 
returned to lactation and could produce sufficient milk to maintain 
' . 
them in the herd. Another animal came back in lactation but had to 
be removed because .of uneconomical production. 
Further, Kulkarni (25) treated two buffaloes which had aborted 
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in late pregnancy and had not fully developed udders were not "letting 
down" milk properly. They were treated with Leptaden after treating 
genitalia with antibiotics. There was a gradual induction of "letting 
down" and after 15 days of Leptaden treatment, they showed increased 
milk yields . 
Two weak animals with problems of pyometra received Leptaden 
after the treatment of genitalia with antibiotics (25). Both of the 
animals showed increases in their milk yields. Four out of five 
buffaloes which recovered from foot and mouth disease responded to 
Leptaden treatment. 
Kaikini et. al. (24) carried out systematic studies of Leptaden 
therapy and observec_i its effects · on milk yield, expulsion of placenta, 
· and problem cases of milk letdown in Nagpuri and Murrah buffaloes 
(Indian breeds) maintained under controlled farm conditions. When 
buffaloes having a history of habitual irregularity in milk letdown 
were treated with Leptaden at the rate of 10 tablets twice daily for 8 
10 
days, milk yields increased significantly starting on the sixth day of 
tr:eatment. Milk yield increases ·ranged from one to three liters per 
head per day and were maintained for 50 to 60 days after terminating 
the Leptaden treatment. Further, none of these treated animals showed 
any irregular milk letdown after treatment. 
In some .farm management practices, the calf is allowed to 
suckle its dam before milking. Death of the calves usually causes 
stoppage of milk secretion in Murrah buffaloes. These problem cases 
responded to Leptaden treatment with increased milk yields ranging 
from 2 to 3 liters per day (24). 
Buffaloes with deer.eased milk yield due to retained placenta 
and still-births, responded 100% to Leptaden therapy (24). The 
increase in milk yield was from 1 to 5 liters. 
These worker's (24) overall results indicated a decidely positive . 
increase in the milk yield of Leptaden-fed buffaloes compared to the 
untreated control group. They found it to be safe and economical, 
giving increased returns in the form of enhanced, persistent milk 
·yield. 
Recent studies of Narasirnhamurthy (32) concerned the 
galactopoietic action and the mechanism of action of Leptaden. 
Cross-bred cows of the same ages and the same stages of lactation 
were used. The type and quantities of rations were constant with no 
,· i , 
additional feed allowance provided for extra milk produced. Leptaden 
was. fed to the cows at the rate of 10 tablets twice daily for 14 days 
following a 21-day pre-treatment period. The average milk yield gain 
in Leptaden-fed anima_ls from pre-treatment period to treatment period 
was 13% while the control animals' yield decreased 7. 5%. Thus the 
total integrated response of Leptaden therapy was 20. 5% (13. 0% + .. 
7. 5%) of pre-treatment yields. The treated group maintained the high 
yield over the control group even after the Leptaden treatment was 
discontinued. The fat content of the milk of the Leptaden-fed 
animals increased more than that of the controls. His experimental 
evidence suggested that the chief property of gaiactopoiesis of 
Leptaden was not similar to thyroprotein feeding. 
Pharmacology of Leptaden 
Leptaden tablets (Alarsin) contain the extracts of two indig-
enous medical plants, Leptadenia reticulata (Jeevanti) and Breynia 
pa tens (Kamboji), in equal proportions (134 mg each). Leptadenia 
reticulata is mentioned as a stimulant and tonic and Breynia patens 
as an astringent. There is no mention in the books of Ayurveda or 
modern books of Indian indigenous drugs about the use of these 
drugs in gynaecological disorders or lactation. Although the useful-
ness of Lepta den in cases with history of threatened abortions, 
11 
habitual abortions, still-births, premqtu_re deliveries, and its 
lactogenic properties both in human beings and animals have been 
reported by several research workers ( l, 33, 34) its pharmacological 
values have not been well established (38) . 
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Shrivastara et. al. (38) reported that the LDS0 of the alcoholic 
extract of Lept~den was 750 mg/kg while that of Leptadenia reticulata 
and Breynia patens was 1000 mg/kg. The extracts in general produced 
calmness with slight porosis in mice. There was no significant effect . 
on electroshock seizure. _ High doses caused depression followed by 
labored respiration and convulsions . Leptaden injected intrave·nously, 
(10 mg/kg) produced significant dec~_eases in blood pressure which 
were blocked by atropine. Extracts of Breynia pa tens injected 
intravenously in doses of 5 to 20 mg/kg, produced a transitory 
biphasic fall in blood pressure. Repetition of the dose diminished 
the hypotensive effeqt but the pressure response became evident. 
Leptadenia reticulata in the same dose produced a prolonged fall in 
blood pressure. Pre-treatment with atropine or mepyramine maleate 
did not affect the hypotensive property significantly in either case. 
These extracts did not show any marked effect on respiration, but 
spasmogenic activity on isolated smooth muscle preparations was 
observed. 
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Anjaria and Gupta (2) fed Leptaden to mature virgin rabbits in 
gro"ups of 3 each f,or 12 days at the rate of 187. 5 mg daily. No change 
in mammary gland development wa~ observed by daily visual examina-
tion. This suggested· that the drug may not possess an estrogenic 
property as its lactogenic activity. Pharmacological experiments 
on dogs indicated the prolonged hypotensive action of the drug which 
may be due to peripheral vasodilation. Chemical investigation 
indicated the drug possessed sterols and sugars. Narsimhamurthy (32) 
did not .find any iodine in Leptaden tablets. 
Experimental work of Sharma (3 7) on the isolated rat uteri 
indicated that Lepta-den has an oxytocic property. This property 
was, however, not destroyed by sodium thioglycollate incubation 
indicating that the active principle is not oxytocin itself. These 
findings confirmed beneficial effects of Leptaden in cases of retained 
placenta. The oxytocic property may also be responsible for the 
increase in milk yields associated with its use in women as well 
as in animals. 
The experimental work of Narsimhamurthy (3 2) indicates that 
the chief galactopoietic property of Leptaden is not similar to 
thyroprotein feeding. The drug may have some action on the nervous 
system, pc1rticularly the hypothalamus, inhibiting the release of a 
prolactin-inhibiting factor. 
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EXPERIMENTAL PROCEDURES 
Three trials were conducted at the Dairy Research and Producti ·· 
Unit at South Dakota State University. 
Trial I 
Four Brown Swiss and two Holstein cows in late lactation were 
paired on the basis of milk production, age and breed and placed i n 
individual stanchions. One cow of each pair was randomly assigned 
to the Leptaden and the other to the no-Leptaden (control) group. 
This trial was initiated November 24, 1969, and terminated on 
January 2 6 , 19 7 0 • 
Feeding aI?-d management were kept identical in both of the 
groups throughout the experimental periods. The cows were fed 
twice daily, using the same hay, silage and grain mixtures that had 
been fed prior to the experiment while the cows were in a free stall 
barn. Individual feed intake data were recorded. The grain mixture 
. was fed at the rate of 1 kg for 2 kg of milk yield. The composition of 
the grain mixtures is shown in Table 1. Seven kilograms of alfalfa 
hay was offered to e a ch cow and the weigh-backs recorded. Corn 
silage was given free choice and the excess was weighed back. 
The experiment was divided into three periods of three weeks 
each; pre-treatment, trea tment and post-trea tment. During the 
TABLE 1. Composition of the grain mixture. 
Ingredients 
Corn 
Oats 
Soybean oil meal 
Dicalcium phosphate (dikal) 
Urea 
Trace mineral salt 
Vitamins A and Da 
Quantity 
(kg} 
929.9 
616.9 
204.1 
22.7 
18.1 . 
22.7 
a3 2, 000 IU Vitamin A and 5000 IU Vitamin D added per cow daily. 
pre-treatment period both groups of animals received the same ration 
and got used to the change in environment from the free stall to the 
stanchion barn. During the treatment period the cows in the Leptaden 
· group· received 1 C Leptaden tablets 1 (Sg} twice daily with their grain 
mixture. During the post-treatment period Leptaden was not fed to 
any cows. 
1 Alarsin Pharmaceuticals, Bombay, India. 
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Each cow was weighed once at the start of the experiment and 
once each week during the trial. Daily milk production of all cows 
' . 
was recorded. Milk samples were taken on the third week of each 
period and ana.lyzed for milk fat by the Babcock method (44) and total 
solids by the Mojonnier method (3). Rectal temperatures and 
respiratory rates were checked once during pre-treatment, treatment, . . 
and post-treatment periods. Blood samples were taken during the 
third week of each period and examined for differential leucocyte 
counts, total red blood cells (RBC), white blood cells ("WBC), 
hemoglobin (Hb) percent and hematocrit (HCT) values by standard 
procedures (8). In a.ddition, protein-bound iodine was estimated 
by the Hycel Cuvette PBI method (21),. Blood sugar levels were 
determined (44) along with blood minerals---calcium, phosphorus, 
and magnesium (5). Leptaden tablets were analyzed for iodine by 
the method of Binnerts ( 4) . 
Trial II 
This trial was initiated January 19, 1970, and concluded 
March 16, 1970. Six cows, two Brown Swiss and four Holsteins 
in early lactations were used in this trial. They were paired as in 
Trial I with one cow of each pair randomly assigned to the Leptaden 
16 
and the other to the no-Leptaden group. Feeding and management 
wer~ kept identical in both the groµps throughout the experimental 
period and followed the same schedule as outlined in Trial I. 
The experiment was divided into three periods, pre-treatment, 
treatment, and post-treatment. The pre-treatment period was for 
two weeks duration. During this period the cows of both groups 
received the standard ration. The treatment period lasted for three 
weeks. During this period the cows assigned to Leptaden were fed 
15 Lepta den tablets twice daily with the concentrate mixture. The 
post-treatment period was three weeks. 
Body weights C?f all the cows in this trial were taken every 
week (Monday). Daily feed consumption and milk production of all 
cows were recorded. Rectal temperatures and respiratory rates were 
checked during pre-treatment, treatment, and post-treatment periods. 
Milk samples were taken during the final week of each period and 
examined for fat and total solids. Differential leucocyte counts, 
total° RBC, WBC, Hb, and HCT values were estimated during each 
period. The general health of the animals was checked regularly. 
Protein-bound iodine (PBI}, blood minerals and blood sugar levels 
were determined in pre-treatment and treatment periods. 
17 
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Trial III 
This trial commenced March 23, 1970, .and concluded May 24, 
1970. Four Holstein and two Brown Swiss cows in mid-lactation 
were paired as previously and assigned rand9mly to the Leptaden 
and the no-Leptaden groups -as described in Trial I and Trial II. 
The feeding and ·management were kept identical for both groups 
throughout the experimental period. Regular alfalfa hay, corn 
silage, and grain mixture were- fed and the feed intake recorded 
for each ·cow. 
Following a three-week pre-treatment period, cows in the 
Leptaden group were administered 15 Leptaden tablets twice daily 
by means of a metal balling gun throughout the three-week treatment 
period. This period was succeeded by a three-week post-treatment 
period. Daily milk production and weekly body weights were 
recorded as in previous trials. Heart rates, rectal temperatures, and 
respiratory rates were checked during pre-treatment, treatment and 
post-treatment periods. Milk samples were examined for fat and 
total solids during the third week of each period. General health 
of the animals was checked reguiarly. 
18 
Statistical Analysis 
Steel and Torrie (41) have described all the statistical analysis 
applied to these ·data. The technics of analysis of variance were 
applied to the data us_ing F test in order to make the necessary 
comparisons and tests of significance. The total sum of squares 
was parUtioned into components by which it was possible to test 
the significance of treatments, trials, periods as well as their 
interactions. The interpretation of the analysis of variance and 
tests of significance as used in this research is restricted to the 
particular levels of drugs, trials, and periods. 
19 
RESULTS AND DISCUSSION 
Body weights 
A summary of the effects of Leptaden on the average body 
weight changes in the three trials is presente~ in Table 2. The body 
weights of individual cows in Trials I, II, and III are recorded in 
Appendix tables · i, 2, and 3 respectively. 
TABLE 2. Average body weight changes. a 
Period · Group Average · 
body weight 
(kg} 
Pre-treatment No Leptaden 626.6 
Leptaden 649.6 
Treatment No Leptaden 615.3 
Leptaden 648.1 
Post-treatment No Leptaden 613.1 
Leptaden 648.6 
a Average of three trials. 
The average loss o(body weight during the experimental period 
was 13. 5 kg and 1. 0 kg per cow for the no-Leptaden (control) and 
Leptaden groups, respectively. However, this differe.nce in body 
20 
weights between the no-Leptaden and Lep~aqen groups was not 
statistically signif~cant. During Trial I the average gain in body 
weight per cow was 23. 8 kg while i.n the Leptaden group it was only 
3. 0 kg. The cow 849 in Leptaden group lost 5. 2 kg body weight 
which accounted for the difference in weight gain between the two 
groups . In Trial· II, cows in both groups lost body weights. The 
average loss of body weight per cow in the no-Leptaden group was 
21 
10. 4 kg compared to 12. 4 kg body weight loss in the Leptaden group. 
There was a gain of 6. 9 kg in body weight per cow in the Leptaden 
group in Trial HI. The no-Lepta den group lost 5 7. 6 kg body weight 
per cow. There was· great individual variation in body vrnight changes 
during these three trials. It was expected that the Leptaden, by 
virtue of its tonic and stimulant actions, would enhance the body 
weights of the cows. However, these breeds of cows under different 
regimen of feeding and management did not respond to the drug. On 
the whole, Leptaden did not show any detrimental effects on the 
general health of these animals. 
Feed Intake 
The average daily feed intake of cows is summarized in Table 3. 
Appendix tables 4, 5, and 6 show the feed intake of individual cows 
in Trials I, II, and III respectively. · Leptaden did not show any 
. ·i ' 
significant effects on average daily feed intake. However, the trial 
effeqts were significant for grains, hay (P <.01) and silage (P < . 05). 
The variation in hay consumption during different periods (period 
effects) was significant (P <. 01). 
TABLE 3. Average daily feed intake. a 
Period Group Grain Hay Silage 
22 
---------- {kg) -----------
Pre-treatment No Leptaden 9.8 4.2 16.2 
Leptaden 9.9 4.0 18.3 
Trea t."ncnt No Leptaden 9.6 3.1 17.3 
Leptaden 10.0 2.7 17.& 
Post-treatment No Leptaden 10.1 3.1 17.9 
Leptaden 10.2 2.9 17.7 
a Average of three trials. 
Milk Yield 
Table 4 indicates that cows receiving Leptaden did not produce 
more milk than the controls. In Trial I, all the cows were in late 
lactation. Although Leptaden and no-Leptaden groups showed a 
further decline in production, the decrease in milk yield of the treated 
group was greater than in the untreated group. Cow 963 of the 
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TABLE 4. Average daily milk production, fat and to.tal solids content. a 
Period Group Milk Fat Total 
production solids 
(kg) (%) (%) 
Pre-treatment No Leptaden 23.5 4.3 13. 1 
Leptaden 23.8 4.5 13.3 
Treatment No Leptaden 24.0 4.5 13. 5 
Leptaden 24.0 4.4 13.0 
Post-treatment No Leptaden 22.0 4.2 13.7 
Leptaden 22.0 4.4 13. 4 
a -
Average of three trials. 
group was primarily responsible for the greater milk yield decline in 
that group, decreasing from 13. 2 kg to 8. 6 kg milk per day during 
the experimental period (Appendix table 7). In Trial II, the cows 
in both groups were in early lactation. There was a gradual decline 
in the milk production curves in both groups. However, the average 
decrease in production per cow in the control group was slightly 
higher (1. 9 kg) than the Leptaden_ group (1. 1 kg).. In the third trial 
also, the cows did not respond to the Leptaden treatment. The 
average decrease in milk yield per cow in Leptaden group was 2. 9 kg 
against 2 . 3 kg of the control group. 
lit,.·-r ·~· 
~-t· 
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The variations in milk yields of the cows in different trials 
(trial. effects) were highly significant. In Trial I, the Leptaden tablets 
were fed at the rate of 1 O tablets twice daily per cow. Because of 
the lack of effect of Leptaden on milk production at this dose, a higher 
level ( 15 tablets twice daily per cow) of the drug was used in the 
second and third trials. Leptaden, even at the higher level did not 
show any galactopoietic effect. This lack of effect on milk yield is 
difficult to reconcile with the powerful effects recorded by 
Narasimhamurthy, Moulvi and others (2, 30, 32). There have, · 
however, been other experiments in which no significant increase was 
observed in the Lept~den-fed animals (43). 
Milk Fat and Total Solids 
It is evident from Table 4 that the fat content of milk of the cows 
in the no-Leptaden group is not significantly different from that of the 
Leptaden group. Without attaching much importance to the statistical 
significance in the difference between the fat yields of the Leptaden-
fed cows and controls, Narasimhamurthy (3 2) reported to have obtained 
an average gain in the fat yield in treated animals. The integrated 
response of the Leptaden tablet was 33. 6% of the pre-feeding yields. 
However, this is not in agreement with our results. Total solids· 
content of the milk showed the same trend as milk fat content. In 
Trial I the average gain in fat was O. 2% for the controls compared 
to O. 2% decrease in the Leptaden group. Trial II shows an increase 
in the fat content of both the groups. This increase is O. 3% for 
controls and O. 4% for the Leptaden-fed animals. On the contrary, 
both the groups showed a decline in their fat contents of milk in the 
third trial. The controls had O. 8% decrease and the treated had O. 5% 
decrease. The figures for the total solids for Trials I, II and III 
are presented in the Appendix tables 7, 8 and 9 respectively, along 
with milk yield and fat contents. Statistical analysis of these ~ata 
did not show any significant difference between the treated and 
·control groups. The average total soilds content of the milk was 
found to be about 13 % in both the groups during the three periods. 
Heart Rates, Respiratory Rates, and Rectal Temperatures 
Respiratory rates and the rectal temperatures of the cows were 
recorded during each period in all the three trials. Heart rates were 
checked only in the third trial. The data are given in the Appendix 
tables 10, 11 and 12. The average heart rates, respiratory rates, 
and rectal temperatures are shown in Table 5. The average heart 
beats per minute per cow was 65 for the no-Leptaden and Leptaden 
groups--during the pre-treatment periods. The average heart beats 
of the no-Leptaden gr.oup remained the same during treatment periods 
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TABLE 5. Average heart rates, respiratory rates, and rectal 
temperatures. 
Period Heart Respiratory 
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Rectal 
. ratea rateb temperaturec 
(per min) (per min) 
Pre-treatment No Leptaden 65 
Leptaden 65 
Treatment No Leptaden 65 
Leptaden 67 
Post-treatment No Leptaden 74 
Leptaden 76 
a Average heart rates of Trial III. 
bAverage respiratory rates of three trials. 
cAverage rectal temperatures of three trials. 
20 
20 
20 
20 
21 
20 
(OC) 
38.2 
38 .3 
3 8. 3 
38.3 
3 8-. 3 
38.3 
while that of the Leptaden group increased from 65 to 6 7. In the 
post-treatment period both of the groups showed increased heart 
rates. The average heart beats for the no-Leptaden group was 74 
· per minute and t~at of Leptaden group was 76 per minute. This 
increase is not statistically significant although the period effects 
were significant (P <· 01). 
The average respiratory rates per minute per cow were 20 in 
both the groups in all periods except that the no-Leptaden group had 
an average of 21 per minute during the post-treatment period. The 
rectaJ temperatures, shown in Table. 5, indicate that Leptaden did 
not affect the body temperatures. Statistical analysis did not show 
any significant difference in respiratory rates and rectal temperatures 
between the two groups. On the whole, the r·espiratory rates, rectal 
temperatures and heart rates of all the cows involved in this study 
were within the normal physiological ranges in all periods. 
Protein-bound Iodine (PBI) 
Since iodine is present in thyroxine, interest in it is almost 
. entirely concerned with disorders of the thyroid gland. Under normal 
conditions, almost all the blood iodine is in the plasma. Less than 
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a third of this is present as inorganic iodine compounds, the remainder 
being organic and bound to protein. The nature of all this protein-
bound iodine (PBI) is not known. About two thirds of the PBI appears 
to contain thyroxine or compounds which behave similarly. Hence 
variations · in PBI are related to changes in activity of the thyroid. 
The level of iodine present in the plasma both in health and 
disease is so small that the determination is not easy and requires 
great care. Modj_fication and refinements of the technic have 
brought the serum PBI concentration to a high degree of accuracy 
as an index of thyroid function. Serum PBI level between 3. 5 µg to 
8 yg per .100 ml is cmnsidered as n~rmal. PBI values below 3. 5 µg 
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per 100 ml are suggestive of hypothyroidism and above 8 J.lg per 100 ml 
as hyperthyroidism ( 6, · 7) . 
Therapy with inorganic iodides or iodine, the administration of 
iodinated compounds and thyroactive materials produce false high _ 
PBI levels which last for days, months or even years depending on the 
agent and mimics hyperthyroidism (7, 35). Abnormalities of serum 
proteins such as those in some liver disorders and in nephrosis may 
. be associated with a lowering of PBI (26, 36). Salicylates lower the 
PBI in experimental animals (15). It is unlikely that sex, season, 
age or climatic conditions influence the level of the blood iodine 
although it has been found to increase during pregnancy (44). 
The PBI may sometimes give a more reliable index of thyroid 
abnormalities than measurements of basal metabolic rate. The Hycel 
curvette PBI method (21) is reliable, providing satisfactory 
reprodu_cibility, specificity, recovery and elimination of cross-
contamination. This procedure was followed in this research to 
estimate the levels of the serum PBI and to determine the thyroid 
activities of the Leptaden-fed cows. 
Table 6 summarizes the average PBI levels of both groups of 
cows in three expe1imental periods. During the preliminary period 
the average PBI level of a control cow was 6. 2 7 µg ·per 100 ml 
against 6. 52 µg per 100 ml of a Leptaden-fed cow. The average 
a 
TABLE 6. Levels of protein-bound iodine (PBI) and blood sugar. 
Period Group PBI Blood sugar 
(µg per 100 ml) (mg per 100 ml) 
Pre-treatment No Leptaden 6.27 59.7 
Leptaden 6.52 63.5 
Treatment No Leptaden 6.77 44.7 
Leptaden 6.88 47.7 
·Post-treatment No Leptaden 6.35 II O '> ,:v. ,.J 
Leptaden 6.83 51. 8 
aAverage of first and second trials. 
level of PBI increased from 6. 2 7 to 6. 7 7 µg per 10 0 ml in control 
cows during the treatment period and decreased to 6.35 pg per 100 
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ml in the post-treatment period. The average PBI level of the Leptaden-
fed cows increased from 6. 52 to 6 88 µg per 100 ml during the treat-
ment period and slightly declined to 6. 83 µg per 100 ml in the 
post-treatment period. No. significant difference was observed 
between the two groups; however, trial effects were found significant 
(P <. 05). These results indicated that Leptaden did not impair the 
thyroi d a c tivity of t hes e breeds of cows eve n at a higher level. 
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Blood Sugar 
Blood sugar leyels of the cows ·were estimated during pre-treatment, 
treatment, and post-treatment periods . of first and second trials. The 
average level of blood sugar per cow in the control group was 59. 7 mg 
per 100 ml against 63. 5 mg per 100 ml of that of Leptaden-fed cows 
(Table 6). During the treatment period the blood sugar levels of the 
controls decreased to 44. 7 mg per 100 ml while it decreased to 4 7. 7 mg 
per 100 ml in case of the n6-Leptaden fed cows. During the post-
treatment period the average _blood sugar level per control cow was 
48.3 mg per 100 ml and that ·of Leptaden-fed cows was 51.8 mg per 100 
ml. Leptaden feeding did not elevate the blood sugar l_evels of the cows 
significantly. However, the interactions between treatments and trials, 
trial effects and period effects were significant (P <..01). The inter-
actions between trials and periods were also found significant (P <. 05). 
None of the cows during the experimental period revealed the symptoms 
of hyperglycemia. 
Calcium, Phosphorus, and Magnesium 
The levels of calcium, phosphorus and magnesium in the blood 
serum of the cows of both groups were determined during the three periods 
of Trial I and during the pre-treatment and treatment periods of Trial II. _ 
The average values are presented in Table 7 and details are given in 
Appendix Tables 15 and 16. Statistical analysis did not show any 
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significant variations in the levels of calcium, phosphorus and magne-
sium fn the blood serµm of the cows of the control and the treated groups. 
a TABLE ·7. Levels of calcium, phosphorus, and magnesium in blood. 
Period Group Calcium Phosphorus Magnesium 
-------- (mg per 100 ml) --------
Pre-treatment No Leptaden 5.0 8.6 
Leptaden 5.0 9.1 
Treatment No Leptaden 5.0 9.6 
Leptaden 5.0 9.7 
Post-treatment No Leptaden 5.0 7.7 
Leptaden 5.0 8.4 
aAverage of first and second trials. 
White Blood Cells {WBC), Red Blood Cells (RBC), 
Hemoglobin {Hb), Hematocrit {HGT), and 
Differential Leucocyte Counts 
1.0 
1.5 
0.8 
1.0 
0.9 
0.8 
Certain hematologic procedures in the examination of experimental 
animals without relation to any known or suspected diagnosis are worth 
considering. The findings of these examinations indicate whether or not 
more deta iled examinations are required. A normal number and distri-
bution of cells and a normal hemoglobin concentration in the blood are 
so importa nt as physiological constants that the absence of disease 
can sca rce ly be ass erted until these observa tions have b e en made (8). 
In this study blood samples of all the cows were examined for 
hemoglobin (Hb), hematocrit (HCT), white blood cells (WBC) , red 
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blood cells (RBC) a nd differential leucocyte counts during pre-·treatment, 
treatment and post-treatment periods of first and second trials. Table 
8 and Table 9 show the average values while Appendix tables 17, 18, 
19 and 2 0 present the detailed blood picture of all the cows involved 
in the study during first and second trials. The hemoglobin content, 
hematocrit readings, total erythrocyte counts, total leucocyte counts, 
and differential leucocyte counts were within the normal physiological 
ranges . Leptaden treatment did not change the blood picture of the 
TABLE 8 . White blood cells (WBC), red blood c ells (RBC), hemoglobi7:1 
(Hb) and hematocrit (HCT) values. a 
Period Group WBC RBC Hb HCT 
(thousands (millions (gm per (%) 
per cu mm) per cu mm) 100 ml) 
Pre-treatment No Leptaden 7.23 6.73 11. 8 34 
Leptaden 7.81 6.98 11. 6 34 
Treatment No Leptaden 7.29 7.23 11.1 34 
Leptaden 7.50 8.0 11. 3 35 
Post-treatment No Leptaden 6. 3 9 7.55 12. 1 35 
Leptaden 7.95 8.57 12.2 36 
a Average of first and second trials. 
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TABLE 9 . Differential leucocyte counts. a 
Period Group Neutro- Lympho- Mono- Esono- Baso-
2hils cytes cytes 2hils 2hils 
------ {percent of total count) ------
Pre-treatment No Leptaden 33 64 1 2 0 
Leptaden 32 64 1 3 0 
Treatment No Leptaden 32 66 1 1 0 
Leptaden 33 64 1 2 0 
Post-treatment No Leptaden 34 63 0 3 0 
Leptaden 33 64 0 3 ·O 
a_Aver0.ge of first and second trials. 
cows. Similar results have also been reported by Narasimhamurthy (32). 
The Leptaden tablets were analyzed once during the first and 
second trials for iodine using the method of Binnerts (4). The iodine 
content of the tablets was found to be only O. 9 ppm. This low level 
of iodine indicates that the drug does not work as do preparations 
of iodine in stimulating milk yield. The drug contains 105 0 ppm iron. 
This high level of iron in Leptaden may be responsible for its reported 
tonic and stimulant properties. 
Research with buffaloes and cows in India indicates that 
Lepta den has a powerful galactopoietic property. This galactopoietic 
property of the drug is said to be due to its oxytocic property (3 7) . 
Narasimhamurthy (32) has indicated· that the drug might have some 
actio~ on hypothalamus, inhibiting the release of prolactin-inhibiting 
factor. His arguments supporting this explanation for the increased 
milk production appear to be sound. 
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Leptaden did not stimula te milk production or increase fat content 
of the milk produced by the cows used in this study. This lack of 
response to the drug is difficult to explain in light of the previous 
India~ work. It is suggested that an increase in milk production 
associated with exogenous administration of a hormone(s) indicates 
a sub-optimal secretion of that hormone(s) (16). It may be possible 
that the Indian cows and buffaloes do not have the optimum secretion 
of the hormones responsible for increased milk production. This idea 
is substantiated by the work of Bindery and Turner (20). They reported 
that although thyroxine injection of cows elevated milk production, 
some showed an average decrease in milk production. A favorable 
response is interpreted to mean· less than optimal thyroxine secretion 
and a limited response in some cows might indicate that thyroxine 
secretion is already optimum. Experiments with dairy cows using 
preparations of prolactin or oxytocin show similar results (12, 13). 
The level of milk secretion is related to the degree of thyroid 
activity (10). Thyroids in dairy cows are more active than those of 
beef cattle. Hot weather decreases thyroid activity, raises rumen 
propi-onate and butyrate at the expense of acetate and lowers milk 
fat (40). Johnson and Ragsdale (22) have reported that climatic 
conditions affect thyroid activity and rumen metabolism of cattle. 
Both of these physiological functions are believed to be clearly 
associated with tbe production potential of cattle. Lowering of the 
environmental temperature raises the basal oxygen consumption, 
increase the uptake, release and turnover of the thyroidal iodine, 
accelerates the degradation of organic iodine, raises the fecal and 
urinary excretion of labeled iodine and finally, results in increased 
thyroidal epithelial height and goitrogenesis. It may be possible that 
the Indian cows and buffaloes have poor thyroid activities compared 
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to the cows used in this study. The PBI levels of the Indian cows 
appear to be lower than that of the cows used in our experiment {32). 
Studies at Missouri (2_2) indicate many distinct, consistent, individual 
differences in the thyroid activity of animals. There is a striking 
decline in thyroid activity on exposure to the higher environmental 
temperature. A negative correlation between thyroid activity and 
temperature for each breed raised at each temperature was obtained. 
Breeds of cows differ in their thyroid activities. The climatic condition, 
regimen of feeding and management, difference in breed and thyrold 
activities and hormona l regulation of Indian cows are some possible 
factors responsible for increased milk production following the 
administration of Leptaden tablets. 
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· Lepta den failed to exert its galactopoietic effect on these breeds 
of cattle under a different environmental condition and regimen of 
feeding and management than in India . The feed intake and body 
weight changes did not indicate its reported tonic and stimulant 
properties. Absence of elevated PBI level, relative lymphocytosis and 
a lowered erythrocytosis count indicate the non-existence of hy.per-
thyroidism. This conclusion has further been substantiated by the 
of cows under Lepta den treatment. On the whole, Lepta den did not 
impair the thyroid activities of these cows. The routine examination 
of temperature, respiration and pulse along with blood analyses 
indicated that Leptaden has no observable detrimental effect on the 
health of cows. 
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SUMMARY AND CONCLUSIONS 
Ah experiment .consisting of three trials was conducted to deter·-
. mine the effects of feeding Leptaden to dairy cows. The study was 
concerned with the effects of the herbal drug Leptaden on milk 
production and composition, on thyroid activity and on other physio-
logical activities: 
The cows were in late, early and middle stages of lactation in 
Trials I, II and III respectively. The breeds of cattle used in the 
study were Holstein and Brown Swiss. Leptaden (Alarsin Company) 
was fed at the rate of 10 tablets (0. 5g/tablet) twice daily in the first 
trial and 15 tablets twice daily in the second and third trials. Daily 
feed consumption and milk production records were maintained. Body 
weights were taken every week. Heart rates, respiratory rates and 
rectal temperatures were checked during each period. Milk samples 
were examined for fat and total solids; blood samples for hemoglobin, 
hematocrit, white blood cells, erythrocyte count and differential 
leucocyte count. Special blood tests were conducted for protein-bound 
iodine, blood glucose, calcium, phosphorus and magnesium. These 
analyses were made during the third week of each period. 
Leptaden feeding did not show any significant effects on average 
feed intake. Both the control groups and the experimental groups lost 
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body weight during the trials but there was _no significant difference 
in weight loss betw~en the groups. · Leptaden-fed cows did not show 
an increase in milk production, fat GOntent or total solids compared 
to the controls. Heart rates, respiratory rates and rectal temperature 
of all cows involved in the study were within normal ranges in all 
periods. The serum protein-bound iodine and blood glucose levels 
indicated that Leptaden did not impair thyroid activities of the cows. 
The drug had no observable adverse effects on the general health of 
the cows. Differences in climatic conditions, feeding, management, 
breed, thyroid activities _and hormonal regulation are some possible 
factors responsible for the galactopoietic property of Leptaden found 
with Indian cows but not found with cows used in this study. 
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Appendix Table 1. Average body weight changes during trial I. 
Cow Group Period Body weight 
number 
(kg) 
857 No-Leptaden Pre-treatment 580 . 8 
Treatment 592.6 
Post-treatment 601.9 
942 No-Leptaden Pre-treatment 522.1 
Treatment 529 . 6 . 
Post-treatment 552. 0 
2783 N o-Leptaden Pre-treatment 582.9 
Treatment 588 . 8 
Post-treatment 603 . 4 
849 Leptaden Pre-treatment 624.4 
Treatment 618.7 
Post-treatment 619.2 
963 Leptaden Pre-treatment 666.7 
Treatment 669.3 
Post-treatment 671. 8 
2797 Leptaden Pre-treatment 552.5 
Treatment 560.4 
Post-treatment 561. 6 
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Appendix Table 2. Averag e body weight changes during trial II. 
Cow ,Group Period Body weight 
numbe r 
(kg) 
955 No-Leptaden Pre-treatment 627.8 
Treatment 623. 2 
Post-treatment 624.6 
2695 No-Leptade n Pre-treatment 63 8. 2 
Treatment 624.4 
Post-treatment 616.4 
2 741 No-Lepta den Pre-treatment 647 . 7 
Treatment 639. 8 
Post-treatment 641. 4 
919 Leptaden Pre-treatment 711. 2 
Treatment 687.7 
Post-treatment 683. 1 
2692 Leptaden Pre-treatment 617 . 7 
Treatment 613.5 
Post-treatment 613.7 
2735 Leptaden Pre-treatment 734.4 
Treatment 726.2 
Post-treatment 729.2 
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Appendix Table 3. Average body weight changes dudng trial III. 
Cow Group 
number 
Period Body weight 
(kg) 
919 No-Leptaden Pre-treatment 646.4 
Treatment 630.5 
Post-treatment 619.2 
2735 No-Leptaden Pre-treatment 711. 7 
Treatment 668. 6. 
Post-treatment 660.9 
2872 No-Leptaden Pre-treatment 681. 8 
Treatment 640.0 
Post-treatment 596.9 
955 Leptaden Pre-tr ea tm ent 645.5 
Treatment 651. 4 
Post-treatment 65 7. 3 
2561 Leptaden Pre-treatment 613.9 
Treatment 623.6 
Post-treatment 610.5 
2947 Leptaden Pre-treatment 679.9 
Treatment 682.2 
Post-treatment 692.2 
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Appendix Table 4. Average daily feed intake during trial I . 
Cow Group . Period Grain Hay Silage 
number 
------- (kg) -------
857 No-·Leptaden Pre-treatment 6.6 2.7 19.4 
Treatment 6.3 2.2 21.1 
Post-treatment 6.9 2.0 21. 3 
942 No-Lepta den Pre-treatment 7.0 1.5 14.9 
Treatment 6.3 1. 3 . 17. 6 
Post-treatment 6.0 1. 2 1"6.9 
2 783 No-Leptaden Pre-treatment 6.9 1. 6 9.2 
Treatment 7.6 1. 9 19.3 
Post-treatment 8.2 2. 1 20.0 
849 Leptaden Pre-treatment 6.9 2. 1 22.5 
Treatment 6.9 1. 4 17.6 
Post-treatment 6.9 1.5 19.0 
963 Leptaden Pre-treatment 7.5 2.5 21. 7 
Treatment 6.2 2.2 19.7 
Post-treatment 5.0 2.3 21. 6 
2 797 Lepta den Pre-treatment 6~9 1.0 13.3 
Treatment 7.4 1. 7 17.7 
Post-treatment 7.7 2.0 15.4 
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Appendix Table 5. Average daily feed intake during trial II. 
Cow · Group Period Grain Hay Silage 
number 
------- (kg) -------
955 No-Leptaden Pre-treatment 10.7 5.8 15. 1 
Treatment 11. 7 3.3 13.6 
Post-treatment 11. 8 4.0 17.7 
2695 No-Lepta den Pre-treatment 13.9 7.4 16.3 
Treatment 10.5 3.7 10.9 
Post-treatment 12.7 4.5 13.6 
2741 No-Leptaden Pre-treatment 11. 6 6.7 17.5 
Treatment 11. 8 4.0 16.4 
Post-treatment 10.9 4.0 17.7 
919 Leptaden Pre-treatment 10.8 7.4 17.2 
Treatment 9.9 3.7 12.2 
.Post-treatment 10.9 4.0 14.2 
2692 Leptaden Pre-treatment 14.0 6.4 15.4 
Treatment 13.2 2.5 13.5 
Post-treatment 13.6 3.2 14.2 
2735 Leptaden Pre-treatment 11. 7 ·s. 2 13.8 
Treatment 12. 1 3.7 13.4 
Post-treatment 12.7 4.1 17.3 
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Appendix Table 6. Average daily feed intake during trial III. 
Cow Group . Period Grain Hay Silage 
number 
------- {kg) -------
919 No-Leptaden Pre-treatment 8.2 4.5 16.6 
Treatment 8.2 3.4 18.7 
Post-treatment 9.1 2.8 17.6 
2735 No-Leptaden Pre-treatment 11. 8 3.2 16.5 
Treatment 11. 8 3.5 18.1 
Post-treatment 12.3 3.3 14.8 
2872 No-Leptaden Pre-treatment 11. 8 4.3 20.2 
Treatment 11. 8 4.4 20.3 
Post-treatment 12.7 3.9 21. 7 
955 Leptaden Pre-treatment 10.0 4.6 21. 7 
Treatment 10.0 3.9 21. 0 
Post-treatment 10.9 3.2 19.8 
2561 Leptaden Pre-treatment 10.6 2.9 16.4 
Treatment 13.5 2.5 17.1 
Post-treatment 12.7 2.8 14.2 
2947 Leptaden Pre-treatment 10~9 4.2 22.9 
Treatment 10.9 2.8 26.2 
Post- treatment 11. 8 2.8 23.4 
Appendix Table 7. Average daily milk production, fat and total solids 
content during trial I. 
Cow Group Period Milk Fat Total 
50 
number 2roduction solids 
(kg) (%) (%) 
857 No-Leptaden Pre-treatment 11. 8 4.6 13. 7 
Treatment 12.7 5.5 14.4 
Pos t-trea tme nt 12. 7 5.3 13.3 
942 No-Leptaden Pre-treatment 13. 2 4. 1 13.6 
Treatment 12.2 4.2 14.0 
Post-treatment 10.4 4.3 13.4 
2 783 N o-L2ptaclen Pre-treatment 13. 2 4.2 12.7 
Treatment 15. 9 5.3 14.0 
Post-treatment 15. 0 4.0 12.9 
849 Leptaden Pre-treatment 13.2 5.3 14.8 
Treatment 13.6 5.2 14.6 
Post-treatment 13.2 5.4 14.9 
963 Leptc_den Pre-treatment 13. 6 5.4 14 .7 
Treatment 10.4 4.6 13.2 
Post-treatment 8.6 5.3 15.0 
2797 Lepta den Pre-treatment 12.7 4.4 13.2 
Treatment 15.4 3.8 12 .. 2 
Post-treatment 13.6 3. 7 12 . 7 
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Appendix Table 8. Ave.rage daily milk production, fat and total solids 
content during trial II. 
Cow Group Period Milk Fat Total 
number 2roduction solids 
{kg) (%) (%) 
955 No-Leptaden Pre-treatment 28.1 4.8 13.4 
Treatment 29.9 5.5 14.9 
Post-treatment 28.1 4.4 13.4 
2695 No-Leptaden Pre-treatment 32.2 3.2 11. 5 
Treatment 34.9 3.5 12.1 
Post-treatment 27.7 3.9 12.4 
2741 N o-1.eptaden Pre-treatment 29.0 3 ,. 7 12 , 4 
Treatment 29.0 4.3 12. 9-
Post-treatment 26.8 4.3 13.2 
919 Leptaden Pre-treatment 25.9 4.5 14.1 
Treatment 26.8 5.2 14.3 
Post-treatment 24.9 4.9 13. 9 
2692 Leptaden Pre-treatment 31. 3 3.5 10.0 
Treatment 34.5 3.7 11. 0 
Pos t-trea tme nt 31. 3 3.9 12.6 
2735 Leptaden Pre-treatment 32.7 4. 1 12.6 
Treatment 33.6 4 .1 12.2 
Post-treatment 30.4 4.4 12.7 
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Appendix Table 9. Average daily milk production, fat and total solids 
content during trial III. 
Cow Group Period Milk Fat Total 
.number 12roduction solids 
(kg) (%) (%) 
919 No-Leptade n Pre-treatment 22.7 5.6 14.7 
Treatment 21. 8 4.5 13.7 
Post-treatment 21 _-3 4.9 14.1 
2 735 N o-Leptade n Pre-treatment 31. 3 5.0 13.5 
Treatment 30.4 4.1 12.5 
Post-treatment 27.7 3.5 12.2 
?.070 
L.t V / '-' No-Leptade11 Pre-treatment 29.9 3.8 12.7 
Treatment 29.5 3.6 12.9 
P.ost-treatment 28.1 3.6 12.7 
955 Leptaden Pre-trea trnent 24.9 5.0 14.0 
Treatment 21. 8 5.7 14.8 
Post-treatment 20.9 4.6 13.7 
2561 Lepta::ien · Pre-treatment 33.6 4.6 14 . 3 
Treatment 34.5 4.3 13.0 
Post-treatment 30.8 3.9 12.7 
2947 Leptaden Pre-treatment 26.3 3.9 12.5 
Treatment 25.4 3.5 11. 9 
Post- treatme nt 24 .5 3.6 12 . 3 
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Appendix. Table 10. Average respiratory rates, and rectal temperatures 
during trial I. 
Cow Group Period Respiratory Rectal 
number rate tern fbera ture 
(per min) ( C) 
857 No-Lepta den Pre-treatment 22 38.3 
Treatment 16 38.6 
Post-treatment 18 38.1 
942 No-Leptaden Pre-treatment 20 38.1 
Treatment 18 38.2 
Post-treatment 18 38.3 
2783 i'Jo..,Leptaden Pre-treatment 22 38.2 
Treatment 20 38.6 
Post-treatment 22 38.2 
849 Leptaden Pre;..treatment 20 38.4 
Treatment 15 38.4 
Post-treatment 18 38.4 
963 Leptaden ·Pre-treatment 22 38.3 
Treatment 18 38.1 
Post-treatment 20 38.6 
2797 Leptaden Pre-treatment 26 38.6 
Treatment 17 38.2 
Post-treatment 20 38.6 
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Appendix Table 11. Average respiratory rates, and rectal temperatures 
during tria 1 II . 
Cow Group Period Respiratory Rectal 
number rate temoerature 
(per min) (°C) 
955 No-Leptaden Pre -treatment 22 37.9 
Treatment 18 38.3 
Post-treatment 18 38.0 
2695 No-Leptaden Pre-treatment 20 38.3 
Treatment 20 38.6 
Post-treatment 22 38.5 
2741 No-Lepta den Pre-trecitment 22 38.l 
Treatment 18 38.2 
Post-treatment 18 38.1 
919 Leptaden Pre-treatment 20 38.1 
Treatment 18 38.4 
Pos t-trea tm ent 18 38.1 
2692 Lepta den Pre-treatment 20 38.0 
Treatment 20 38. 1 
Post-treatment 18 37.8 
2735 Leptaden Pre-treatment 24 37.9 
Treatment 20 38.1 
Pos t-trea tm ent 20 38.2 
S'S 
Appendix Ta.ble 12. Average heart rates, respj_ratory rates, and rectal 
temperatures during trial III. 
Cow Group Period Heart Respiratory Rectal 
numbe r rate rate temgera ture 
(per min) (per min) ( C) 
919 No-Lepta den Pre-treatment 64 16 38.3 
Treatment 62 24 38.2 
Post-treatment 76 26 38.5 
2 735 No-Lepta den Pre-treatment 64 16 38.6 
Treatment 62 22 38.3 
Post-treatment 76 26 38.4 
2872 No-Leµtaden Pre-Lreatment 68 , (") J.O ') () ') v O • v 
Treatment 70 22 38.1 
Post-treatment 72 22 38.2 
955 Leptaden Pre-treatment 62 17 38.5 
Treatment 68 22 38.3 
Post-treatment 72 22 38.1 
2561 Leptaden Pre-treatment 66 18 38.4 
Treatment 70 26 38.3 
Post-treatment 80 26 38.3 
2947 Leptaden Pre-treatment 66 18 38.6 
Treatment 64 24 38.4 
Post-treatment 76 24 38.4 
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Appendix Tab le 13. Levels of protein-bound iodine (PBI) and blood 
sugar during trial I. 
Cow Group Period PBI Blood 
number sugar 
(µg per 100 ml) (mg per 100 ml) 
857 No-Leptaden Pre-treatment 7.6 55 
Treatment 6.4 40 
Post-treatment 6.3 54 
942 No-Leptaden Pre-treatment 8.9 57 
Treatment 7.8 45 
Post-treatment 7.5 57 
2783 " No-Le ptaden Pr~-trorl trn orit 6.8 7 ') I L., 
Treatment 5.8 50 
Post-treatment 5.2 52 
849 Lepta den Pre-treatment 7.5 65 
Treatment 8.5 48 
Post-treatment 8.7 70 
963 Leptaden Pre-treatment 6.9 73 
Treatment 7.2 60 
Post-treatment 7.3 67 
2 797 Leptaden Pre-treatment 8.0 67 
Treatment 6.7 60 
Post-treatment 6.1 60 
Appendix Table 14. Levels of protein-bound iodine (PBI) and blood 
sugar during trial II. 
Cow Group Period PBI Blood 
. number sugar 
(µg per 100 ml) (mg per 100 ml) 
955 No-Leptaden Pre-treatment 4.8 55 
Treatment 5.8 38 
Post-treatment 6.3 40 
2695 No-Leptaden Pre-treatment 5.5 67 
Treatment 6.9 55 
Post-treatment 6.8 50 
r) '7 II 1 
I "i. J. No-Leptaden Pre-treatment 4.0 52 
Treatment 7.9 40 
Post-trec;3.tment 6.0 37 
919 Leptaden Pre-treatment 6.3 58 
Treatment 9.5 40 
Post-treatment 8. 1 42 
2692 Leptaden Pre-treatment 4.9 56 
Treatment 4.2 40 
Post-treatment 6.0 38 
2735 Leptaden Pre-tr ea tm ent 5.5 62 
Treatment 5.2 38 
Post-treatment 4.8 34 
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Appendix Table 15. Levels of calcium, phosphorus,· and magnesium 
in blood during trial I . . 
Cow Group Period Calcium Phosphorus Magnesium 
. number 
------ (mg per 100 ml) ------
857 No-Leptaden Pre-trea tment ·s, o 5.2 2.0 
Treatment 5.0 7.9 0.5 
Post-treatment 5.0 5.0 1. 7 
942 No-Leptaden Pre-treatment 5.0 12.0 1.5 
Treatment 5.0 8.8 0.5 
Post-treatment 5.0 6.0 0.5 
') 70') No ~Lspta.don Pm- tree! tmcnt 5.0 1 ') () 1 () '-tlVV .I.'-' • V .I.• V 
Treatment 5.0 13.0 0.5 
Po s t-trea tm ent 5.0 12.0 0.5 
849 Leptaden Pre-treatment 5.0 8.8 4.4 
Treatment 5.0 2.5 0.5 
Po st-tr ea tm ent 5.0 6.0 1. 3 
963 Leptaden Pre-treatment 5.0 16.0 2.0 
Treatment 5.0 16.0 1.5 
Post-treatment 5.0 10.0 0.5 
2797 Leptaden Pre-treatment 5.0 8.8 1.0 
Treatment 5.0 13.0 0.5 
Post-treatment 5.0 9.2 0.5 
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Appendix Table 16. Levels of calcium, phosphorus, and magnesium in 
blood during pre-treatm~nt a nd trea tment pe ri ods 
of trial II. 
Cow Group Period C,alcium Pho s phorus Magne sium 
number 
------ (mg per 100 ml) ------
955 No- Leptaden Pre-treatment 5.0 6.0 0.5 
Treatment 5.0 13.0 1. 6 
2695 No-Leptaden Pre-treatment 5.0 2.5 0.5 
Treatment 5.0 2.5 0.5 
2741 No~Leptaden Pre-treatment 5.0 11. 0 0.5 
Treatment 5.0 11. 0 1. 6 
919 Leptaden Pre-treatment 5.0 6.0 0.5 
Treatment 5.0 8.9 0.5 
2692 Leptaden Pre-treatment 5.0 6.0 0.5 
Treatment 5.0 8.9 2.0 
2 735 Leptaden Pre-tr ea tm ent 5.0 9.2 0.5 
Treatment 5.0 8.9 1. 6 
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Appendix Table 17. V\Thite blood cells (WBC), red · blood cells (RBC), 
hemoglobin (Hb), and hematocrit (HCT) value s 
during trial I. -
Cow 
number 
Group Period VvBC RBC Hb HCT 
(thousands (millions (gm pe r (%) 
per cu mm) per cu mm) 10 0 ml) 
85 7 No-Lepta den Pre-treat. 6.00 
Treatment 7. 50 
Post-treat. 6. 5 0 
942 No-Leptaden Pre-treat. 9.00 
Treatment 8.00 
Post- treat. 7. 75 
2 783 No-Leptade n Pre-treat. 5.80 
849 Leptaden 
963 Leptaden 
2 79 7 Leptaden 
Treatment 7. 30 
Post-treat. 10. 00 
Pre-treat. 6.50 
Treatment 6. 3 0 
Post-treat. l _0. 15 
Pre-treat. 7.25 
Treatment 6. 28 
Post-treat. 8. 10 
Pre-treat. 5.00 
Treatment 6. 2 8 
Post-trea t. 9. 95 
5.15 
5.77 
6.2 
5.44 
6.81 
n ,.. , 
0. .L 
5.79 
7.15 
8.59 
5.82 
8.90 
8.51 
7.44 
8.90 
8.04 
5.47 
6.99 
9.63 
10.7 
9.9 
12.0 
11.1 
9.7 
13. l 
11. 4 
11.1 
12.5 
11. 3 
11. 8 
13. 1 
13.1 
12.3 
13.4 
11. 8 
10.1 
11. 9 
30 
32 
34 
33 
30 
39 
32 
33 
34 
32 
36 
39 
39 
36 
3 4 
35 
35 
34 
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Appendix Table 18. White blood cells (WBC), red blood cells (RBC), 
hemoglobin (Hb), and h~matoc1it (HCT) values 
during trial II. 
Cow Group Period WBC RBC Hb HCT 
number 
(thousands (millions (gm per (%) 
per cu mm) per cu mm) 10 0 ml) 
955 No-Leptaden Pre-treat. 6.70 8.35 12.4 35 
Treatment 7.10 8.20 12.5 37 
Post-treat. 6.00 7. 50 11. 6 35 
2695 No-Lepta den Pre-treat. 7.10 8.73 12.8 35 
Treatment 6.95 8.40 11. 5 34 
Post-treat. ? ? n 7.67 11. 6 32 ,_, • .... V 
2741 No-Lepta den Pre-treat. 8.80 7.15 12.3 35 -
Treatment 6.90 7.03 11. 8 34 
Post-treat. 5.90 6.81 11. 6 32 
919 Leptaden Pre-treat. 8.70 7 .11 10.5 32 
Treatment 10.10 6.98 11. 0 32 
Post-treat. 7.70 6.80 11. 6 32 
2692 Leptaden Pre-treat. 10.55 7.13 11.1 32 
Treatment 8.75 7.23 10.5 32 
Post-treat. 3.90 8.04 11. 6 33 
2735 Leptade n Pre-treat. 8.90 8.91 11. 8 33 
Treatment 7.30 9.01 12.0 35 
Post-treat. 7.9 3 9.90 11. 8 35 
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Appendix Table 19. Differential leucocyte counts during trial I. 
Cow Group Period Neutro- Lympho- Mono- Esono- Ba so 
number 2hils cytes cytes Qhils Ehils 
---:-----(percent of tota l count)------
857 N o-Leptaden Pre-treat. 18 80 2 
Treatment 23 76 0 1 
Post-treat. 38 62 
942 No-Lepta den Pre-treat. 30 67 3 
Treatment 39 58 3 
Post-treat. 39 61 
2783 No-Leptaden Pre-treat. 14 83 3 
Treatment 46 52 1 1 
Post-treat. 30 64 6 
849 Leptaden Pre-treat. 24 72 4 
Treatment 39 59 2 
Post-treat. 36 63 1 
963 Leptaden Pre-treat. 23 67 1 9 
Treatment 35 62 3 
Post-treat. 29 65 6 
2797 Leptaden Pre-treat. 13 81 5 1 
Treatment 29 68 1 3 
Post-treat. 23 75 2 
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Appendix Table 20. Differential leucocyte count during trial II. 
Cow Group Period Neutro- Lympho- Mono- Esono- Baso-
number 12hils cy:tes cytes 12hils 2hils 
----:--~-(percent of total count)-------
955 No-Lepta den Pre-treat. 55 43 2 
Treatment 30 70 
Post-treat. 32 66 2 
2695 No-Lepta den Pre-treat. 51 48 1 
Treatment 39 61 
Post-treat. 34 66 
2 741 No-Lepta den Pre-treat. 33 64 2 1 
Treatment 14 80 6 
Post-treat. 30 62 8 
919 Leptaden Pre-treat 50 47 3 
Treatment 20 73 7 
:f:>ost-trea t. 31 66 3 
2692 Leptaden Pre-treat. 48 50 2 
Treatment 46 52 2 
Post-treat. 27 69 4 
2 735 Leptaden Pre-treat. .36 63 1 
Treatment 32 68 
Post-treat. 48 48 4 
